Oncotarget

Reviews:

Functional and therapeutic significance of EZH2 in urological cancers

Xiaobing Liu, Qingjian Wu and Longkun Li _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:38044-38055. https://doi.org/10.18632/oncotarget.16765

Metrics: PDF 2331 views  |   HTML 3464 views  |   ?  


Abstract

Xiaobing Liu1, Qingjian Wu1 and Longkun Li1

1 Department of Urology, Second Affiliated Hospital, Third Military Medical University, Chongqing, China

Correspondence to:

Longkun Li, email:

Keywords: EZH2, histone methyltransferase, prostate cancer, bladder cancer, kidney cancer

Received: November 24, 2016 Accepted: March 04, 2017 Published: March 31, 2017

Abstract

The enhancer of zeste homolog 2 (EZH2) is a core subunit of the polycomb repressor complex 2 (PRC2), which is overexpressed in numerous cancers and mutated in several others. Notably, EZH2 acts not only a critical epigenetic repressor through its role in histone methylation, it is also an activator of gene expression, acting through multiple signaling pathways in distinct cancer types. Increasing evidence suggests that EZH2 is an oncogene and is central to initiation, growth and progression of urological cancers. In this review, we highlight the critical role of EZH2 as a master regulator of tumorigenesis in the prostate, bladder and the kidney through epigenetic control of transcription as well as a modulation of various critical signaling pathways. We also discuss the promise and challenges for EZH2 inhibitors as future anticancer therapeutics, some of which are currently in clinical trials.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16765